Galapagos achieves multiple milestones in rheumatoid arthritis alliance
In October 2007, Galapagos announced an alliance agreement with Janssen Pharmaceutica NV providing Janssen with option rights to acquire worldwide, commercial licenses to novel small molecules from up to 12 of Galapagos' internal programs involving rheumatoid arthritis therapeutic targets. The milestones announced today are the result of several of these programs reaching the next phase of medicinal chemistry optimization.
"We are pleased that the molecules derived under the rheumatoid arthritis alliance have met the agreed upon criteria," said Onno van de Stolpe, CEO of Galapagos. "Galapagos continues to deliver high quality research and remains on course for achieving its goals for the year."
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.